Gossamer Bio Completes Enrollment for Phase 3 Study

Gossamer Bio ( (GOSS) ) just unveiled an update.

On June 16, 2025, Gossamer Bio announced the completion of enrollment for its global Phase 3 PROSERA Study, which evaluates seralutinib in Functional Class II and III PAH patients. The study, conducted in collaboration with the Chiesi Group, aims to identify patients likely to benefit significantly from treatment, using criteria informed by the Phase 2 TORREY study. The completion of enrollment marks a significant step in developing seralutinib as a potential first-in-class treatment option for PAH. The company expects to announce topline results in February 2026, which could impact its operations and industry positioning.

The most recent analyst rating on (GOSS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Gossamer Bio stock, see the GOSS Stock Forecast page.

Spark’s Take on GOSS Stock

According to Spark, TipRanks’ AI Analyst, GOSS is a Underperform.

The overall stock score for Gossamer Bio is low, primarily due to significant financial challenges, including high leverage and consistent losses. While there is some improvement in revenue and cash flow, the company remains unprofitable. Technical analysis suggests market uncertainty, and valuation metrics show limited attractiveness due to a negative P/E ratio and no dividend yield.

To see Spark’s full report on GOSS stock, click here.

More about Gossamer Bio

Gossamer Bio is a late-stage, clinical biopharmaceutical company focused on developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company aims to be an industry leader and improve the lives of patients with pulmonary hypertension.

Average Trading Volume: 1,548,451

Technical Sentiment Signal: Buy

Current Market Cap: $281.9M

See more insights into GOSS stock on TipRanks’ Stock Analysis page.